Good afternoon. My name is Peter, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Inspire Medical Systems Q3 2021 Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. Thank you. Megan Rowekamp, Director of Financial Reporting at Inspire, you may begin the conference. Thank you all for participating in today's call. Joining me are Tim Herbert, President and Chief Executive Officer, and Rick Buchholz, Chief Financial Officer. Earlier today, we released financial results for the three and nine months ended September 30, 2021. A copy of the press release is available on our website. On this call, management will make forward-looking statements within the meaning of the federal securities laws. All forward-looking statements, including, without limitation, those relating to our operations, financial results and financial condition, investments in our business, continued effects of the COVID-19 pandemic, full year 2021 financial and operational outlook, and improvements in market access are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements. See our filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q filed with the SEC today, for a description of these risks and uncertainties. Inspire disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and speaks only as of the live broadcast today, November 2, 2021. With that, it is my pleasure to turn the call over to Tim Herbert. Tim? Thank you, Megan. Thanks everyone for joining the call today for our third quarter 2021 business update. I am pleased to report today that the Inspire team once again delivered extremely strong results in the third quarter as we continue to focus on commercial execution and leveraging the increased number of hospitals and ASCs offering Inspire therapy. This increased capacity provided additional flexibility during the quarter, especially with the regional challenges of the COVID resurgence. In addition, our improved process of connecting patients with healthcare providers, including through our AdvisorCare program, has steadfastly increased the number of patient consultations regarding Inspire therapy. First, revenue results were very strong. In the third quarter, we generated worldwide revenue of $61.7 million, which was an increase of 72% compared to the third quarter of 2020. This growth was driven by several factors, including the increased patient demand for Inspire therapy, our ability to improve patients' access to care with our AdvisorCare program, the increased capacity and performance at new and existing centers, the positive reimbursement environment for Inspire therapy, and finally, the significant impact the pandemic had on procedures in 2020. Due to the continued spread of the Delta variant during the third quarter, we experienced an impact on our business in many regions across the U.S. However, since our centers are geographically distributed across the country and not overly concentrated in any one particular area, the impact was localized and therefore minimized. In addition, the rise in COVID cases moved through the impacted areas relatively quickly, with normalized procedure volumes resuming in a relatively short order. Another important factor minimizing COVID-related impacts in these areas was our ability to work with implanting centers to schedule procedures at new centers and shift some procedures to regional hospitals and ASCs less affected by the resurgence. Additionally, Inspire is not considered an elective procedure in many hospitals. That fact, coupled with the consideration that Inspire is an outpatient procedure, provided additional flexibility for implanting centers to continue to perform Inspire cases. With this progress, we continue to have confidence in the outlook for our business during the remainder of 2021. As such, we are increasing our full year 2021 revenue guidance to a range of $219 million-$221 million from our previous guidance of $210 million-$213 million. This guidance represents an increase of 90%-92% over full year 2020 revenue. As always, I would like to reiterate that our primary focus remains on the patients to ensure that each and every one has the best possible outcome from Inspire therapy. Our ongoing research and clinical programs are tracking patients' progress and experience with Inspire therapy. As an example is the ADHERE Registry, which is planned to enroll 5,000 patients. Currently, we have over 3,400 patients enrolled. During the third quarter, the investigators published the results of the first 1,800 patients and reported clinically relevant reductions in AHI and quality of life measures, as well as a patient satisfaction score exceeding 90%. We remain committed to the ongoing research to further improve patient outcomes. With that, let's now get into the details surrounding the third quarter, beginning with capacity. During the quarter, we added 68 new U.S. implanting centers, extending the period with a total of 603. This is well above our prior guidance of adding 48-52 new centers. We continue to experience a growing demand for new centers, as well as physicians seeking to add Inspire therapy to their practices. With this continued strong demand, we are increasing our guidance and now expect to open 52-56 new centers during the fourth quarter of the year. This increase in new centers includes a growing number of ASCs, which offer a more efficient care setting and now make up 20% of our total U.S. centers. We will continue to add both hospitals and ASCs going forward and expect to see a growing percentage of Inspire procedures being performed in the ASCs. Regarding the U.S. sales team, we created 11 new sales territories in the third quarter, bringing our total to 141, and we expect to maintain this strong pace during the fourth quarter. Therefore, we are increasing our guidance and now expect to add 11- 12 new territories in the fourth quarter. We also increased the number of field clinical representatives by adding 10, ending the third quarter with 71. Further, we remain dedicated to scaling our sales management and training teams to optimize our ongoing expansion and focus on the strong patient outcomes and center productivity. As such, during the third quarter, we expanded the number of area vice presidents from four to seven and created two zone senior vice presidents, new positions that oversee the area vice presidents. We are proud that all of these positions were filled with promotions from inside the organization. This is our ongoing plan cadence to scale the U.S. business in a controlled manner to grow the adoption of Inspire therapy while maintaining quality and again, strong patient outcomes. Regarding productivity, as expected, growth between new and existing centers has shifted such that a higher percentage of the growth is attributed to existing centers. More specifically, through the first nine months of 2021, approximately 70% of our growth was the result of increased procedures at existing centers and approximately 30% have come from newly added centers. Again, we need to be careful with these percentages due to the significant impact the pandemic had on procedures in 2020. We believe that our growth will be more balanced moving forward. As part of growing center utilization, we need to continually improve our ability to assist interested patients with making a connection with a qualified healthcare provider. To start, the outreach programs continue to be very effective in generating interest in Inspire therapy, primarily through the inspiresleep.com website. We have recently changed the Inspire site to provide more educational content to ensure patients have a good understanding of Inspire therapy as well as the process of working with their healthcare provider to discuss and be prescribed Inspire therapy. For the first nine months of 2021, the number of visitors to our website was approximately 5.3 million, an increase of 45% year-over-year. From these visits, we had approximately 72,000 physician contacts, representing a significant 69% year-over-year increase. Now, there are two contributing elements to these physician contacts. One is through Community Health Talks and the second is through our AdvisorCare program. After tracking these for some time, we characterize the Community Health Talks as more educational, and most appointments originate from the AdvisorCare. As such, moving forward, we will report on the physician contact only through the AdvisorCare, as this provides greater accuracy when we're looking at appointments and therapy conversion rates. We will certainly continue to support Community Health Talks, as this provides the physicians the opportunity to speak with several potential patients in a live group session or via Zoom meeting to answer questions that they may have about Inspire therapy. Focusing on the performance of our AdvisorCare, we ended 2020 with approximately 180 of our centers using the ACP. Today, we have over 450 centers on the ACP. Through the first nine months of 2021, this equates to approximately 13,500 contacts generated through the Advisor Care Program alone. As we noted on our last call, we launched the second version of our ACP in the third quarter with a new, larger, and more experienced vendor with a major call center in San Antonio, Texas. This vendor provides improved scalability, patient community, communication, and data tracking. Most newly activated centers start immediately on the ACP, while existing centers are added through a phased approach. Let's transition to reimbursement and coding. The new dedicated Category I code for Inspire therapy now has received its number designation, and that is 64582. This code is for closed-loop stimulation and covers all elements of the Inspire procedure, and as a result, we believe will ensure reliable coverage and payment. Moreover, because this code is for closed-loop stimulation, it does not describe the therapies of our potential competitors. The new code will formally take effect on January 1, 2022. As a fresh update, CMS just released the commentary regarding the final OPPS rules. In fact, the data files have not yet been uploaded, but will be shortly. Just as a backdrop, the new Inspire Category I code, 64582, was approved to replace the original Category I CPT code, 64568. Back in July, CMS proposed a lower APC payment for the new code, but after reviewing the process, we realized they did not make the connection between the two Category I codes. As such, the Inspire team met with the CMS review panel following release of these proposed rules, and the panel voted unanimously to recommend recalculating the new ASC payment using the data available on the prior year's Inspire implants. From the commentary issued this afternoon, CMS has confirmed that they are accepting the panel recommendation, and we'll await for the final reimbursement calculation. This commentary includes the removal of the multiple procedure discount, which should not have been checked with the original proposal. Further, regarding hospital payments, the new CPT code continues to map to the same level 5 neural ambulatory procedure code or APC. CMS proposed the 2022 payment for this APC to increase by 3% for national average Medicare payment of just over $30,000. Finally, a new Category I code was also approved for the drug-induced sleep endoscopy procedure. The proposed reimbursement for a DISE procedure increased the physician payment from $68 in 2021 to $114 in 2022, a 67% increase. Moving on. Europe also had a strong quarter, driven by increased procedure volumes, particularly in Germany and the Netherlands. Following changes in the reimbursement policy in the Netherlands, we have started training new implanting centers in that country. We expect growth of Inspire to continue in Europe, especially as there has been very limited impact from COVID in recent months. In Asia, we are happy to report the first products have been shipped to Japan in support of the initial implants, which are still planned for later this year. Entry into Japan remains very restricted based on COVID, but we are working with the authorities to have our leading therapy trainer enter into the country to support the initial cases and to reside in Tokyo for the ongoing launch of Inspire therapy. Our partner, Japan Lifeline, has identified several additional centers which will be trained and become operational in 2022. Switching gears to R&D. The adoption of the two-incision implant procedure, which was approved earlier this year, is essentially complete, as 99% of the Inspire procedures are being performed using the two-incision procedure. On the product development side, the team has completed the testing, and this week we formally submitted to the FDA our request for full body MRI compatibility. The FDA was involved during the extensive MRI evaluation process, and we expect approval within the 180 day review window. The next priority is FDA approval of the new patient remote, which we are targeting for later this year. This new device incorporates Bluetooth technology and allows information from the implanted neural stimulator and the patient remote to be uploaded to the Inspire Cloud via patient smartphone. Inspire Cloud is our cloud-based patient management system, and we continue to expand the number of centers in the U.S. and in Europe who are using this tool. The new patient remote significantly adds utility to Inspire Cloud, and we will be conducting a limited launch in the first quarter of 2022 to fully test the interconnectivity and collect feedback from the patients and physicians. We plan full launch of the new patient remote in the second quarter. The next step of our overall digital program is to upgrade our physician programmer, and this project is already in process. This project will allow the programmer to also connect with Inspire Cloud, which is key to the end goal of providing remote patient programming, which we are targeting for 2023. Longer term, the design work for our 5th generation Inspire neural stimulator continues to progress. Once approved, we expect Inspire five to be commercially available in late 2023. The Inspire five device will utilize the existing form factor with plans to maintain the average 11 year battery life without the need for recharging. The Inspire five neural stimulator will provide several enhancements, and most notably, will eliminate the pressure-sensing lead. All sensing will be inside the neural stimulator using an accelerometer to measure respiration. Collectively, these technology enhancements will only further strengthen patient outcomes as well as improve patient and physician experience with Inspire therapy. Finally, I'd like to highlight the recent launch of our first-ever patient experience report in an initiative that provides greater visibility and transparency into clinically reported outcomes and device-related treatment benefits with Inspire therapy. This patient experience report is available on our website. In summary, we continue to experience significant momentum in all key aspects of our business, and our aggressive approach to operating in a COVID environment has resulted in continued growth in the adoption of Inspire therapy. Our focus on patient outcomes and our unique ability to reach and educate potential patients provides us confidence in the continued growth of Inspire. To reiterate, our core focus for 2021 is to increase utilization at our existing centers as well as to increase capacity by opening and training new centers. An important aspect of the anticipated increase in utilization and capacity is the continued expansion of our AdvisorCare program. We remain extremely excited about our future prospects and are confident that we have the appropriate strategy in place to drive long-term shareholder value. With that, I'd like to turn the call over to Rick for his review of our financials. Thanks, Tim. As Tim noted, the Inspire team delivered a robust third quarter and first nine months of the year. Total revenue for the third quarter of 2021 was $61.7 million, a 72% increase from the $35.8 million generated in the third quarter of 2020. U.S. revenue in the third quarter was $58.3 million, an increase of 76% from the $33.1 million generated in the prior year period. The growth in the U.S. reflects a number of factors, including a larger number of implanting centers, broad commercial policy coverage, 100% Medicare coverage that went effective in June 2020, and an increased number of territory managers. In the third quarter, European revenue increased 24% to $3.4 million. The U.S. average selling price in the third quarter was $23,900, which was consistent with the prior year period. The European ASP was $23,500 during the quarter compared to $23,300 in the third quarter of 2020. Gross margin in the third quarter improved to 86% compared to 85.5% in the prior year period due to manufacturing efficiencies and higher sales volume. We continue to expect our full-year gross margin to be in the range of 85%-86%. Total operating expenses for the third quarter were $62.9 million, an increase of 55% as compared to $40.5 million in the third quarter of 2020. This increase was due to the expansion of our sales organization, increased direct-to-consumer marketing programs, continued product development efforts, and general corporate costs. The increase in operating expenses is reflective of our ongoing plan to achieve continued growth and investments in key commercial and development initiatives. Our net loss for the third quarter was $10.3 million compared to the $10.4 million net loss in the prior year period. The net loss per share for the third quarter was $0.38 compared to a net loss of $0.39 per share in the third quarter of 2020. The weighted average number of shares outstanding for the third quarter was 27.3 million. We anticipate that the weighted average number of shares for the fourth quarter will be approximately 27.4 million. As of September 30th, our cash and investments totaled $220.2 million. This strong cash position allows us to remain focused on executing our growth strategy of increasing procedure volume at existing centers and training and opening new implanting centers. With that said, our strong performance and implant trends provide us confidence in our outlook for the remainder of the year. Therefore, as we look forward to the fourth quarter, we are increasing our full year 2021 revenue guidance to a range of $219 million-$221 million from our previous guidance of $210 million-$213 million. This revised guidance represents 90%-92% growth over full year 2020 revenue of $115.4 million. In summary, we have significant and sustainable momentum throughout our business. We remain well positioned to achieve long-term growth. We are extremely pleased with our performance in the first three quarters of the year and are excited to continue executing on our growth strategy. With that, our prepared remarks are concluded. Peter, can you please open up the call to questions? Thank you. To ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Your first question will come from Jon Block with Stifel. Your line is open. Great. Thanks, guys. Good afternoon. Just two for me. First, Rick or Tim, maybe if you can just talk to the 3Q- 4Q cadence. If I take that sort of new midpoint of $220 million for 2021, it implies, I'm calculating $65 million for the fourth quarter, you know, which is up, but it's only up modestly sequentially from the third quarter. That cadence seems different than the past years. Maybe can you just talk to or address, you know, it seems just like a little bit of a conservative 3Q- 4Q 2021 growth rate despite, you know, ongoing momentum, new centers, et c, and then I'll just ask my follow-up. Very good. No, we remain confident. We think we're gonna have a very good fourth quarter. We always put out guidance, as you know, that we're very careful about. We still watch for COVID, and so we make sure we protect against that. We have good momentum with opening new centers and with our AdvisorCare program. We had a pretty strong increase for our guidance. Okay, fair enough. I'll shift gears, Tim, maybe just for you. Broadly, CPAP, what are you hearing? What are you seeing? It seems like ResMed is actually having trouble filling the additional demand per their commentary. I would just love any thoughts on how you see this playing out and, you know, what your conviction is that you might actually see a tailwind from this today versus when the news first broke, whatever that was, three or four months ago. Thanks. We know from the call center that patients identify themselves as users of a Respironics product, and they're affected by the recall. We do know that there are patients coming into our pipeline. We don't have a specific percentage or a number of the impact of that, but we are tracking that to see how broadly that reads across. We certainly know there are patients coming in right now and looking for an alternative therapy. There are patients that simply, with what's transpired, just do not wanna go back to CPAP. Fair enough. I'll follow up offline, guys. Thank you. Sounds great, John. Thanks. Your next question will come from Robbie Marcus with JPMorgan. Your line is open. Robbie Marcus, your line is open. Please check your line if you're muted. I will come back to Robbie. Moving to our next question, we have Danielle Antalffy with SVB Leerink. Your line is open. Hey, good afternoon, guys. Thanks so much for taking the question. Congrats on a really good quarter. Hey ... and thanks for letting me on the call. I have two questions. Just one question is somewhat COVID-related, but really about the hospital labor shortages and just curious how you're factoring. First of all, you're one of the few companies that re-reported thus far that hasn't really called that out as a very meaningful impact. So curious what you did see in Q3 and sort of how you're thinking about that over the next few months. Then I have one follow-up. Yeah, it is a serious concern. We talked on our last earnings call how COVID was already present in Florida and started to move up the coast and did affect different regions across the country. We did experience COVID just like everybody else did, and a lot of that is both hospitalization of patients, but it is because of the staffing shortages. Simply the staff that are in the hospitals are required to take care of the COVID patients and just are not able to take care of other cases, including Inspire. What we have been able to do in some regions is we now have access to ambulatory surgical centers, and so we're able to move some of the cases to the ASCs, including opening up additional ASCs. As we get larger, we also have more flexibility to move cases to suburban hospitals, if you will, where they don't have such a significant impact because of COVID. No, we dealt with COVID just like everybody else did, but we stayed aggressive to be able to take care of the patients. Patients remained motivated to receive Inspire therapy, and we found alternative ways to be able to get the procedures completed. That's gonna continue into the fourth quarter, there's no question about it. Everybody knows that you have the same staffing issues, and it kind of reflects back into John's initial comment on the Q4 cadence. We are gonna work very hard to be able to take care of the patients and find alternative approaches to scheduling their cases at suburban sites or ASCs. Okay, that's helpful. My follow-up was around the number of centers added. I mean, I appreciate that the reimbursement situation will get clarified over the next, you know, in the coming weeks, months, whatever it is. The fact that you guys added so many centers in the quarter with that reimbursement uncertainty plus COVID, to me seems pretty compelling. I mean, can you talk a little bit about some of the drivers of, like, sort of what's driving these centers to come online? The second part of that question, sorry, it's multiple questions in one. That's okay. How quickly they can ramp up to, you know, sort of your higher volume centers. Thanks so much. Yeah. Very good, Danielle. Very great question. Number one, we just don't have enough centers out there. Having just over 600 is still very low penetration in the overall number of hospitals and ambulatory surgical centers available in the United States. We will continue to be aggressive in opening new centers, hence we significantly increased our guidance at opening centers in the fourth quarter, and we are ramping up our overall sales team as well as our training team to be able to continue to increase the cadence of opening new centers. ASCs are a key focus to that. As we mentioned, we're up to 20% of our centers are now ASCs. I think there's confidence, and CMS already mentioned in the commentary that they're accepting of the panel recommendation to recalculate the ASC payment. I think that they had confidence all along that that was going to happen, or they could at least continue with commercial cases. We had a significant number of ambulatory surgical centers open up in the third quarter. Part of that also is with the national contracts that we have in place. We continue to work through the overall number of centers that those corporations have. There's just a lot of runway that we have to be able to continue to open additional centers, and there's motivated physicians at those centers as well as the administrators to get those centers opened up. Did that answer your question or do you have a follow-on on that? No, no. That is perfect. Thank you so much. You bet. Thank you. For your next question, we now have Robbie Marcus with JPMorgan. Great. Can you guys hear me okay? Yep, yep. Robbie, loud and clear. Okay. Take two. First off, congrats on a great quarter. Second, was hoping you could touch on, and sorry if I missed this, I had to come off and on again. It's okay. You know, there was the recall from Respironics in June. We saw ResMed have a benefit from it in this quarter, and obviously they're much earlier in seeing any potential benefits, but they're running into supply issues. I'm wondering, you know, are you starting to see any benefits? I realize it's probably more word of mouth and referrals and implants at this point, and just how you're thinking about that over the next, you know, 6, 12, 24 months. Yeah, we certainly have communications all with all the centers and all the physicians, of course, all of our team on how to communicate with those patients if they have a Respironics device and are unable to benefit or use it anymore and they're looking for an alternative, and Inspire is certainly a viable option for them. We do have several patients that have come through the call center identifying themselves as Respironics patients. We also remember, we still support patients with prior authorizations, and we're able to identify those patients through the prior authorization process, if they're unable to continue with Respironics and are looking for an alternative. We can get them approved through the insurance pipeline. We do have experience with patients from that now. Also remember that just occurring in July, there is a period of time it takes patients to become educated, to get to our website, to get an appointment with a physician, to get diagnosed and prepped for Inspire, get through the insurance. It's a several-month process to transition from CPAP to Inspire. We're still just at the early stages of seeing that benefit, but that will continue in the following year as well. Great. Just a follow-up. You know, your business really diverged from what we've seen from a lot of other companies where third quarter was more materially impacted and seeing lagging volume growth into fourth quarter. You touched on this in the prepared remarks, but I'd love to just hear, you know, what's driving this, you know, how you were able to manage so much better than a lot of other peers, even those that are outpatient-focused. It seems like you've been able to weather the storm a lot better. Would just love any thoughts or insight into that. Thanks. Absolutely. At the top of it's all about motivated physicians and motivated patients. Patients who have untreated obstructive sleep apnea have a significant challenge with quality of life. If they're unable to benefit from CPAP, and you mentioned the Respironics challenges there, they're motivated to find alternatives. We work with those patients and the healthcare providers to find a different approach for Inspire. The next key is we mentioned in the prepared remarks that Inspire isn't really considered an elective procedure in a lot of centers because we are disease state management. Because of that, we get a little bit more priority in scheduling cases. We are purely outpatient, so we don't take up hospital bed. Otherwise, Danielle mentioned there are challenges with staffing issues that we do have to overcome. With our increased number of centers, it gave us the flexibility to move many of these cases to ambulatory surgical centers, for example, in Houston, we could move them to some of the suburban hospitals that aren't necessarily the main COVID centers that didn't have the same staffing challenges. We just have a little bit more flexibility to take care of those patients. We stay very aggressive to find alternative approaches, so we really give our team a lot of credibility to not give up, but continue to keep pushing for the patients and finding an alternative. Great. I appreciate the color. Thanks a lot. You bet, Robbie. Your next question will come from Chris Pasquale with Guggenheim. Your line is open. Thanks, and, congrats on another really strong result. Tim, I know it's. Thanks, Chris. early, but it'd be great to get any early thoughts you have on your 2022 outlook. I mean, for most of our companies, we're looking at easy comps across several quarters next year. Really hard to say that about you guys, given the momentum you've had and how many centers you've added. How are you thinking about the sustainability of the trends that you're talking about here for 4Q, as the calendar rolls over? Well, the first clue we gave you in the prepared remarks is we're scaling our sales management team. We added another structure with senior vice presidents managing zones. We kinda ran out of words there. Having zone senior vice presidents, and each of them having 3-4 area vice presidents, each of them will have an area business manager which will continue to focus on opening new centers, and then each of those area vice presidents having a number of regional managers to be able to continue to grow. We just plan on the ongoing scaling of our operations. Again, we mentioned we only have 600 centers today, but we've increased our guidance going into the fourth quarter here. We expect that we're gonna continue to stay very aggressive at opening new centers. The other side of it that we talked about that really is having an impact is our ability to communicate with potential patients and get them to the AdvisorCare program and our ability to get them appointments with the physicians in the centers. We believe that we're gonna be able to improve our conversion rates going into 2022. As Rick mentioned, we have a program that is sustainable, and we're gonna be aggressive in continuing to find ways to make our therapy available for patients who need an alternative therapy, and especially with CPAP where it is today, that there's certainly an opportunity there. We're excited about our international prospects as well, specifically with Japan with the first order going out, as well as the first implant scheduled. Lots gonna happen in Japan and in Europe and other parts of the world. Thanks. That's helpful. Maybe I'll just piggyback on that last point. It is exciting to see you guys finally getting into Japan. Would love an update on where things stand in Australia, which was another market that you guys had talked a little about. Also any developments on the pediatric front. That seems to have kind of fallen down the list a little bit with all the other stuff you're working on. Absolutely. Australia, we are working with them on the submission of the reimbursement. We're working directly with the physicians now and the minister. We'll have an update later, probably in 2022 on that front. It does have regulatory approval, but again, we're taking the same approach in Japan that we're pretty strict about global pricing and making sure the reimbursement is appropriate for ourselves and the physicians as we open up into new territories. We're in that process of working with Australia on that. Before we jump into pediatrics, I will say that we are doing more strategic work now that we're starting in Japan to look where is our next step, and is it looking at Singapore? Is it looking into Hong Kong and even South Korea? And long term, Mainland China. We're starting to do a little bit of strategic planning along those fronts and look forward to talking more about that in 2022. Pediatrics hasn't gone away. Pediatrics remains an important factor for us. It's why we do what we do, and the benefits that the kids are seeing is tremendous and keeps us very motivated to find alternatives. The studies are open, and we continue to enroll patients there. We are opening additional centers. The majority of the implants continue to be at Massachusetts Eye and Ear in Boston, but we are opening other centers to do more studies. We are doing a post-approval based on the approval we received from the FDA, lowering it down to 18-21. Our goal is to get that age down to 13-15, and not just for children with Down syndrome, but for a broad spectrum of pediatric patients. We do have another study ongoing, talking about the persistence of sleep apnea in adolescents, and as they go from 13- 15 and mature, what happens to their sleep apnea? Does it self-resolve? We don't believe it does, but that's still one of the arguments that we have with the FDA, and we're running that study. Again, it's not a huge market, but it's a very important market, and we're continuing our work on that front. Thanks. You bet, Chris. Thank you. Your next question will come from Amit Hazan with Goldman Sachs. Your line is open. Hey, this is Phil for Amit. Thanks for taking the question. Yeah I think maybe, you know, the question's been asked a lot of different ways. I think maybe if I could drill in just one more time and ask about progression throughout the quarter and kind of the implications for Q4. The question is basically did you see an impact earlier in the quarter, and how did things shape up towards the end of the quarter? What have you seen so far in October that's kind of informing where your guidance is at right now for Q4? We did see an impact in Q3, right? We saw it regionally, and we saw it rotating, right? It was obvious at the beginning of the quarter. We talked about it starting in Miami, and everybody tracked the news, and you saw where COVID traveled. It went up the coast, and when Miami worked through it, then it was up across the three cities, right? Tampa, Orlando, Jacksonville, moved into Atlanta, across to New Orleans. Again, they had to deal with a hurricane. There was a lot of challenges there. But it went into Texas and continued going west and back up north. Every region had to deal with COVID, and the key is being flexible to be able to overcome the challenges and get the cases rescheduled in a timely manner so we don't lose those patients. It's gonna continue on through the fourth quarter. We all know it. Again, Danielle mentioned the staffing challenges that we have across the country. Again, we gotta make sure that Inspire stays at the top of the focus. With that, we wanna be careful about where we put that guidance number out for Q4. We have confidence in our business going forward. We're not slowing down our cadence of expanding number of centers, expanding territory managers, and in fact, we're talking about increasing it with our guidance. We'll continue to work forward and make sure that we always put out those guidance numbers that are carefully selected to make sure that we're able to achieve that. That's great. Thanks so much. The second one. Actually, maybe a two-parter on the reimbursement front. Multitasking a little bit here. Yeah. It looks like the RUC recommended or tried to comment for a slight increase from the PFS rate that was initially proposed, and CMS disagreed with those commenters. I'm interested if you could maybe speak to any feedback that you received from physicians during that interim period between the proposed and the final, and if you expect this to be kind of a point of emphasis or if you're kind of content with where things are at from the PFS side. The secondary question is on kind of the ASC front and if you saw anything from a sort of confusion or a market confusion standpoint that may have temporarily slowed the rate of adoption on that front. I appreciate that you gave us some numbers that look still pretty strong, but maybe a little bit of a deceleration versus what you've given previously. Yeah. Thanks. I don't know about the physician reimbursement. The RVUs that they proposed are really strong. We're okay with that. The physician payment reimbursement rate, actually went down, this year, and that's across the board. That's just not for ENTs, that's every surgeon. I think that usually comes back. That's a little bit of a battle with Congress, but that's all over out of my expertise. Bottom line, I think that $870 national average Medicare payment will sustain, and we'll wait till the final data comes out and see what happens there. As far as, ASCs being affected by, the ruling, no, it hasn't affected anybody yet because it doesn't take effect till January 1, 2022, and they just continued business as usual. They have national contracts with the commercial payers, so don't really think it's affected adoption or impact as of yet. We'll wait till we see the final numbers and still not too concerned going into 2022. We think we'll continue to expand the number of ASCs, whatever the number is. Okay. Thanks for the question. Thank you. Your next question will come from Larry Biegelsen with Wells Fargo. Good afternoon. Thanks for taking the question. Just two for me. Tim, one on Inspire V. Hello. Can you hear me okay, Tim? Yeah, very well, Larry. How are you? Good. What are the milestones to the late 2023 U.S. approval? I had one follow-up. Well, the first step is we're gonna sit down with the FDA in December and show them our whole project plan and show them all of our plans, including how we collected data around the Inspire V and get the FDA's feedback on the program. We're gonna continue with all the development. I have seen fully functional units, and we're gonna be going into detailed testing of those units to make sure that they pass all the qualification testing. The key milestone is, remember, the FDA gets a year to review that. When we're talking late 2023, we need to have that submission into the FDA in 2022, and we remain on target to do that. We'll know more in December 'cause we're being very transparent with the FDA and our whole program. This will be the second time that we've sat down with the FDA to review the project plan. Okay. Let me ask about the Philips recall. I guess it's a two-part question. One is, if you see a benefit, are you going to call it out? You know, because you've been asked a few times on this call, you know, if you've seen the benefit. Are you going to try to quantify it? Because it sounds like you have some information you could try. More importantly, what do you think the long-term implications are of this? I mean, this is a pretty big deal. You know, for example, do you think this could be a catalyst to remove CPAP failure as a requirement for Inspire therapy long term? Thanks for taking the question. Thank you very much, Larry. I think if you really look at the real big picture. What we think is important here is sleep physicians really have to address this with their patients, and they don't have an option to provide an alternative therapy for them. They are really becoming more aware of Inspire therapy and being able to address that and talk to their patients about Inspire. We're making sure that we're taking advantage of the time to communicate with all the sleep physicians to make sure that they have all the knowledge they need. That is turning the cruise ship, as you're referring to, when we're talking about where Inspire sits in the therapy ladder. Right now, I think the key is making sure that the physicians have the right information to be able to take care of their patients and be able to communicate with them. We will continue to track as best as possible the inbound of patients who are affected by the recall and make sure that we're available to help them get to a healthcare provider and get them insurance approval and get them Inspire therapy so they can be treated. These patients are motivated. Really, the long term is a lot of these patients, after having this information given to them, simply do not wanna go back to CPAP. We do think it's gonna have a long-term, positive impact on Inspire, and we're making sure that we're prepared to handle that. Thank you. Thank you, Larry. Your next question will come from Adam Maeder with Piper Sandler. Hey, Tim. Hey, Rick. Congrats on another great quarter here, and thanks for taking the questions. A couple of pipeline questions from my side. First, a multi-parter. I think I heard you say you made the submission for full body MRI labeling with FDA, and you expect a 180-day review time. Hopefully, I have that right. Just any sense for how much of a gating item, you know, MRI labeling has been thus far? Do you think this could be another tailwind to growth, or is it more just kind of continuing the evolution of technology, improving patient experience? And then secondly, with the new Bluetooth-enabled remote, you know, just wondering if there's gonna be any kind of noticeable impact to ASP dynamics or margins. And then I had a follow-up. Got it. MRI, we're available for head coils and for lower extremities, and it's really not been a showstopper. It's just one of those ongoing developments. It's not like we're changing the implanted hardware. What it is, you just need to go through a series of MRI evaluations to show that the amount of energy absorbed by the leads or the heat generated from the procedure isn't harmful, or the current induced by the electromagnetic fields isn't a challenge. We have gone through that testing, and FDA is always kind of aware of that testing ongoing, and they kinda help review those procedures. We'll continue to move forward. The data looks good, and I think it always is another positive for patients that said, "If I can't have an MRI, okay, well, then I might hold off a little bit." I think it just removes one more, obstacles, which is very positive, right? What was your second question there, Adam? Yeah. Thanks, Tim. The second question was just on the Bluetooth-enabled remote, and if there's gonna be any impact to ASP dynamics or margins. Yeah, we're reviewing that right now. I mean, it certainly does add another level of utility to the Inspire Cloud and the physician's ability to manage those patients going forward. We're looking at that very closely, and we'll keep you informed on that. Yeah, it's something that we wanna really consider right now. Okay, fair enough. I'll leave it there. Thanks so much. Very good. Thank you. Your next question will come from Mike Polark with Baird. Your line is open. Hey. Good evening. Just two quick ones. Follow-up on the MRI question. Will the full body labeling be for 1.5 Tesla and 3 Tesla or 1.5 Tesla for now? I don't know. I think it's 1.5 for now, and we're continuing those evaluation. One and a half is in the majority of MRI machines anyway. There's not a lot you're gonna get with a 3 Tesla that you can't get with a 1.5. I think that provides functional settings. The real key to it is making sure that when you get the qualified settings that they are usable. Meaning, you can do a proper MRI to get the proper resolution at the proper energy levels, and that's in effect what we did get qualified. The follow-up was on Japan. I heard, in the prepared remark that the first shipments have been made. Does that mean there's- Any revenue from Japan in this quarter or in the fourth quarter, or will revenue only be recognized when patients are implanted under the distributor model? No. With the distributor, we recognize revenue when we ship it to the distributor. The first units have been shipped, and we will book revenue in the fourth quarter. Okay. Thank you very much. Thank you very much. Your next question will come from Ravi Misra with Berenberg Capital. Your line is open. Hi. Good evening. Hi, Tim. Hi, Rick. Hey, Ravi. I'll just ask both my questions upfront, I guess. Well, first, congratulations to all the sales force members that were promoted. On that sales territory expansion, can you talk to us, you know, you've been kinda tracking above your guidance for the last several quarters, at least, I think, since IPO, actually. How should we think about- That, you know, kind of on an ongoing basis? When do we kind of bring that down? Is this kind of the new level for the next kind of four or five quarters? I guess the second related to that is how do we think about utilization as it goes between the ASC and the hospital and kind of how you see that trending going forward? Maybe one last one. It was a really good kind of free cash flow and profitability quarter against very strong growth. Is this the kinda new normal that we should expect, Rick? Thanks, guys. Very good. All right. Let me do expansion, and then Rick can talk about cash. We wanna continue expanding our sales force, and we are setting the structure to be able to continue that expansion. Hence, we added a level of senior vice presidents, managing area vice presidents, and we reward our talented people by having them move up and have a more influential position in the organization by becoming area vice presidents or regional managers and field clinical reps moving into territory manager positions. That's something that we're just very proud of and will continue. I think the cadence is gonna continue. We're gonna stay aggressive. We're still, when you look at the number of centers, being 600 is very low on the penetration of the overall number of centers that we need to get to be able to serve the demand that we're getting from all the patients. We talked about 5.3 million web hits. We need to continue to grow that, going forward, and we're gonna keep staying aggressive on that. As far as, P&L cash, I'll hand that off to Rick. Yeah. Hey, Ravi. Regarding profitability and cash, we really don't wanna talk about break even just because it's a moving target. We're still very early in the penetration of potential procedures and implanting centers, and we have accelerated our commercial footprint with the addition of new territories as well as additional centers. We're really focused on making investments that will drive years of revenue growth rather than optimizing our operations to produce net income. With that said, we actually did increase our cash position at the end of the third quarter from the second quarter. A couple drivers there included, we did see an improvement in our accounts receivable collections, actually, and we also benefited from. We had $3.8 million of proceeds from the exercise of stock options, which helped the cash increase. I would be careful there because we do have some variability in our burn rate, given the timing of DTC payments as well as development payments, and those can fluctuate on a quarterly basis. We're continuing to make investments. We're leaning forward, and so we do expect that we'll continue to burn cash, going forward, but we did have a strong Q3 from that perspective. Okay. Just that last one. On the ASC utilization versus hospitals, can you just help us think about how you expect that to track? I know there was kind of shifting of cases towards the ASC this quarter, but in general, you know, where do we see that? Yeah. In general, instead of splitting between hospital and ASC, we kind of split it between hospitals recently trained and opened versus some of the older ones that have been opened 2014, 2015, 2016. The key is that we've really changed a lot of our training. We've improved their ability to have patients flow through. The new centers over the last couple years, remember, they opened, and they haven't had to deal with the challenges of prior authorization that we all remember from just three, four years ago, right? They're coming on board with the ability to get a higher utilization right up front, and they start with a higher level of expectation. Both hospitals and ASCs just have that ability to start at a much higher utilization rate. We're happy about that. I do think ASCs will continue to grow as part of the implant. I think hospitals are gonna protect against that. They're gonna also make sure there's plenty of OR time for physicians to perform Inspire cases. Again, our focus is really to kinda keep it balanced between growth and utilization as well as growth at new centers, and new centers will include both hospitals and ASCs. Peter, are you there? Yes, sir. Your next question will come from Suraj Kalia with Oppenheimer. Good afternoon, Tim, Rick. Can you hear me all right? Yes. How are you? Perfect. Tim, congrats on a great quarter. Couple of questions. Thanks. I'll just throw them right up front in the interest of time. Tim, what% of your cases were you successful in moving to regional hospitals or other ASCs, you know, just given everything going on with COVID? Yeah, that's tricky. 'Cause it's all regional, and it's all rotating, right? It's difficult, but I would think a very small percentage actually had to be relocated. But if you talked to the territory managers and area vice presidents in Florida, they would argue that they had a significantly greater number of cases they had to relocate there, as in probably Houston, than they did up here in Minneapolis. Right? The Mayo is able to kind of continue on up here in Minneapolis. I think again, in the affected regions, you had a greater percent, but I don't have a real number I can hand to you. Got it. Tim, you mentioned, and please correct me if I got these numbers wrong, 5.3 million hits on the website, 72,000, I believe, consults, and the math is roughly about 2,500 or so implants in the quarter. Tim, specifically for the ACPs, the 180 centers, and maybe you mentioned this, I must have missed it. Can you give us what the flow-through looks like for these centers? Maybe you could expand on how many implants were done at these ACPs in the quarter. I remember hearing 13,000 worldwide or something. Any clarity would be great. Thank you for taking my question. Yeah. Yeah, I know. Sorry, Suraj. It's so damn confusing because we did throw a bunch of numbers in there. Of the 72,000 contacts, that comes from two sources. Community Health Talks, which really serve to be educational, and those are patients that are not just quite ready yet. They may not make a formal appointment with a physician. They need to think about it and then circle back. Eventually, they come back to the website through the AdvisorCare program. The AdvisorCare program we mentioned had about 13,050 contacts in the third quarter of contacts that they handled directly, and moving those patients forward to make appointments. So that's the part of that 72,000. There's also a lot of centers that are still taking their own phone calls, right? We have 450 centers on the ACP now. There's still a significant number that take their own phone calls, and we're transitioning them over to the ACP as well. As far as flow through, there's a significant number of patients that simply when they contact us, they've never had a sleep study. They need to be referred over to a sleep physician to have a sleep study, and they need to try CPAP first. There are others that just don't qualify, and they need to see a different physician. There are patients, as you mentioned in the past, that when they learn about the technology, they're not ready right away and they wanna think about it some more. There's those patients that really knew what they're looking for. They're understanding it. We're able to educate them, and a significant number are able to get to the physician and hence that's why we have the significant implant numbers and growth rates. Thank you. Absolutely, Suraj. All right. Well, I think, Peter, you got any others there? I'm seeing no further questions at this time. You may proceed, sir. Oh, thank you very much. Thank you all for joining the call today. As always, I am grateful to the growing team of dedicated Inspire employees for their enthusiasm, hard work, and continued motivation to achieve successful and consistent patient outcomes. The Inspire team's commitment to patients remains unmatched and is the most important element to our success. I wish to thank all of our employees as well as the healthcare teams for their continued efforts as we remain focused on further expanding our business in the U.S., Europe, and now Japan. For all of you on the call, we appreciate your continued interest and support of Inspire and look forward to providing you with further updates in the coming months. Please stay safe and healthy. Thank you very much. This concludes today's conference call. Thank you for participating. You may now disconnect.